Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 7/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12390264 | 0.88 | CSNK2A2 (0.44) | PDK2MRGPRX4ALDH1A1L3MBTL1NR1H4 | |
| SCHEMBL12389756 | 0.88 | MAPT (0.45) | PDK2ALDH1A1L3MBTL1MAPK14MAPT | |
| SCHEMBL12365526 | 0.85 | PDK2 (0.41) | PDK2ALDH1A1L3MBTL1MAPK14MAPT | |
| SCHEMBL12389765 | 0.84 | PDK2 (0.48) | PDK2MRGPRX4ALDH1A1L3MBTL1NOTUM | |
| SCHEMBL12389769 | 0.83 | CREBBP (0.40) | PDK2ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12390204 | 0.83 | BRD4 (0.47) | PDK2ALDH1A1MAPK14MAPTRAB9A | |
| SCHEMBL12364995 | 0.83 | PDK2 (0.45) | PDK2ALDH1A1L3MBTL1MAPK14MAPT | |
| SCHEMBL12390394 | 0.82 | HTR2B (0.46) | — | |
| SCHEMBL12389773 | 0.82 | TDP1 (0.40) | PDK2ALDH1A1L3MBTL1MAPK14MAPT | |
| SCHEMBL12365069 | 0.82 | PDK2 (0.43) | PDK2ALDH1A1L3MBTL1MAPK14MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | PDK2 3920/4885MRGPRX4 2358/4885ALDH1A1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.